Does DSCSA apply to compounded peptides?
No. Drugs lawfully compounded under section 503A or 503B are excluded from the Drug Supply Chain Security Act’s definition of “product,” which means DSCSA’s traceability, serialization, and transaction-information requirements do not attach to them.
If a packaging vendor is selling you serialization or chain-of-custody capability on DSCSA grounds for compounded preparations, they are selling against a requirement that does not apply.
We publish this because the error is widespread in our own industry. Several cold chain vendors’ marketing pages describe DSCSA traceability as critical for compounded GLP-1 compliance. It is a confident-sounding claim that collapses on contact with the statute, and it wastes the budget of pharmacies who believe it.
Why compounded drugs fall outside
DSCSA builds an interoperable, electronic, unit-level traceability system across the pharmaceutical supply chain — manufacturers, wholesale distributors, repackagers, and dispensers passing transaction information along a chain of custody. Its scope is set by how the statute defines “product,” and that definition carves out drugs compounded under sections 503A and 503B.
The logic is structural rather than a loophole. DSCSA exists to keep counterfeit and diverted units out of a distribution chain that moves manufactured product through multiple intermediaries. A compounded preparation is made to order by a licensed pharmacy and typically goes directly to the patient or the prescriber. There is no multi-party chain to secure, and no manufactured unit to serialize.
The exclusion covers drugs lawfully compounded under 503A or 503B. It is not a general exemption for anything a pharmacy chooses to make. It also does not reach the ingredients and finished products a pharmacy purchases from manufacturers and wholesalers — when you buy an FDA-approved drug to compound from, that transaction sits inside DSCSA and your supplier’s obligations apply normally.
What actually governs shipping compounded preparations
The absence of DSCSA does not mean the absence of requirements. It means the requirements come from elsewhere, and knowing which authority applies is what lets you build procedures that survive an inspection.
| Source | What it governs | Enforcement |
|---|---|---|
| USP <659> | Storage condition definitions — controlled cold temperature, permitted excursions | Referenced by state rules and accreditation standards |
| USP <1079>, <1079.2>, <1079.3> | Storage and distribution practice, excursion evaluation by MKT, monitoring devices | Informational chapters; referenced by accreditors |
| USP <797> | Sterile compounding, including a section covering handling, storage, packaging, shipping and transport of CSPs | Adopted by most state boards |
| State board rules | Delivery and mailing requirements — written procedures, packaging selection, patient notification, excursion response | Direct. Varies substantially by state |
| PCAB / ACHC accreditation | Shipping system validation, sanitation, light and temperature control | Accreditation status |
| Nonresident licensure | Authority to ship a filled prescription into another state; sterile compounders often need an additional permit | Direct. Per destination state |
| USPS Publication 52 § 453 | Who may mail prescription drugs and to whom | Mailability |
| cGMP (503B only) | Quality system requirements, which pull in distribution controls | FDA inspection |
The practical point: state board rules are where the real teeth are for most 503A pharmacies, and they are moving. Missouri’s prescription delivery rule, effective at the end of 2024, requires written policies ensuring delivery within the temperature requirements recommended by the manufacturer or USP, procedures for selecting packaging, pre-shipment patient notification, and defined actions when an excursion is suspected or confirmed. That is a considerably more specific obligation than anything DSCSA would have imposed.
What to do with the budget
Serialization infrastructure built for a requirement that does not apply is money that could have gone to the things your board and your accreditor will actually ask about: a validated packout, written packing procedures with refrigerant conditioning specified, an excursion response procedure, and documentation showing the validation was done.
If a vendor cannot tell you which specific authority creates the obligation they are selling against, that is the question to keep asking.
Frequently asked questions
Are compounded drugs exempt from DSCSA?
Drugs lawfully compounded under section 503A or 503B are excluded from the DSCSA definition of “product,” so the Act’s traceability and serialization requirements do not apply to them.
Do 503B outsourcing facilities have to comply with DSCSA?
Drugs they lawfully compound under 503B fall within the same exclusion. 503B facilities are separately subject to cGMP requirements, which impose their own quality system obligations including distribution controls — a different and in practice more demanding framework.
Does the exclusion cover the ingredients I buy?
No. Purchasing FDA-approved drugs or other DSCSA-covered products from manufacturers and wholesalers sits inside the Act, and your suppliers’ obligations apply to those transactions normally. The exclusion attaches to the compounded preparation you produce, not to your inbound supply.
Do I need serialization or chain-of-custody data for compounded peptides?
Not on DSCSA grounds. You may still want transit documentation for other reasons — state rules on excursion response, accreditation requirements, or your own quality system — but those obligations come from elsewhere and are satisfied differently.
What replaces DSCSA for compounded preparations?
State board delivery rules, USP <659> and the <1079> series, USP <797> for sterile preparations, accreditation standards from PCAB/ACHC, and nonresident licensure requirements in each destination state.
Why do vendors get this wrong?
DSCSA is well known, sounds authoritative, and maps neatly onto products a vendor wants to sell. The exclusion for compounded drugs is a definitional detail in the statute rather than a headline, so it is easy to skip past — particularly if skipping past it is commercially convenient.
Spend it on the packout instead
Meridian builds validated cold chain packouts sized for pharmacy vial counts. Request a lane test and we will run a sample on your actual route with the chamber data alongside it.
Request a lane testSources
- NCPA, Compounds and raw materials for compounds exempted from DSCSA.
- Drug Supply Chain Security Act, definition of “product”; Federal Food, Drug, and Cosmetic Act §§ 503A and 503B.
- eCFR, 21 CFR Part 216 — Human Drug Compounding.
- Missouri Code of State Regulations, 20 CSR 2220-2.013, Prescription Delivery Requirements.
- ACHC, Compounding Pharmacy: Validating Your Shipping System.
- FDA, cGMP guidance for outsourcing facilities under 503B.